(Q36619159)

15 August 2017

Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor (English)

1 reference

15 August 2017

angiogenesis inhibitor

1 reference

J Horti

1

1 reference

15 August 2017

S C Dixon

2

1 reference

15 August 2017

C J Logothetis

3

1 reference

15 August 2017

Y Guo

4

1 reference

15 August 2017

E Reed

5

1 reference

15 August 2017

W D Figg

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

79

1 reference

15 August 2017

1588-1593

1 reference

15 August 2017

9-10

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690253

15 August 2017

0 references

cites work

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Assay of the antiangiogenic compound TNP-470, and one of its metabolites, AGM-1883, by reversed-phase high-performance liquid chromatography in plasma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

The sulfated polysaccharide-peptidoglycan complex potently inhibits embryonic angiogenesis and tumor growth in the presence of cortisone acetate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Protamine is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Inhibition of angiogenesis in vivo by interleukin 12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690253

7 January 2021

Identifiers

DOI

10.1038/SJ.BJC.6690253

1 reference

15 August 2017

1 reference

15 August 2017

1 reference